Form D · Biotechnology
BEAT BioTherapeutics Corp
Bellevue, WA · CIK 0001574133
Offering snapshot reported Apr 16, 2013 · SEC filing
- Reported sold
- $2.4M Offering amount: $2.5M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 8, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 16, 2013 | Initial | $2,400,000 | No comparison | 21 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-195092
Source: Form D, filed Apr 16, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Kranda | Director, Executive |
| Jim Leggett | Director |
| Greg Mahairas, Ph.D. | Director, Executive |
| Craig Tall | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1380 112 Th Ave. Ne, Suite 200
Bellevue, WA, 98004
Bellevue, WA, 98004